Lexaria Bioscience Corp expected to post a loss of 16 cents a share - Earnings Preview

Lexaria Bioscience

08/07/2025 12:01

Lexaria Bioscience Corp LEXX.OQ LEXX.O is expected to show a rise in quarterly revenue when it reports  results on July 10 (estimated) for the period ending May 31 2025

The Kelowna British Columbia-based  company is expected to report a 8.7% increase in revenue to $91.33 thousand from $84 thousand a year ago, according to the mean estimate from 3 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Lexaria Bioscience Corp is for a loss of 16 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Lexaria Bioscience Corp is $5.50, about 84.1% above its last closing price of $0.87

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Feb. 28 2025
-0.16
-0.15
-0.15
Met
3.2
Nov. 30 2025
-0.12
-0.12
-0.16
Missed
-33.3
Aug. 31 2024
-0.11
-0.14
Missed
-27.3​
May. 31 2024
-0.08
-0.10
-0.13
Missed
-25.8
​​Feb. 29 2024
-0.10
-0.10
-0.06
Beat
40
Nov. 30 2023
-0.11
-0.11
-0.13
Missed
-18.2​
Aug. 31 2023
-0.17
-0.13
-0.12
Beat
11.1
May. 31 2023
-0.25
-0.25
-0.37
Missed
-48

This summary was machine generated July 8 at 11:00 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)